Skip to main content
. Author manuscript; available in PMC: 2016 Sep 15.
Published in final edited form as: J Immunol. 2015 Aug 3;195(6):2552–2559. doi: 10.4049/jimmunol.1501097

FIGURE 6.

FIGURE 6

MS patients have diverse myelin-specific cytokine profiles. (A–C) PBMC were collected from relapsing MS patients with moderate disability on a monthly basis over the course of 1 year. (A) ELISPOT assays were performed to assess the frequency of MBP-specific IFNγ and IL-17 producers. Representative examples are shown. Patients were classified into three groups: IFNγ predominant (n=11), IL-17 predominant (n=7) and IFNγ/IL-17 mixed (n=18), based on criteria described in the Materials and Methods section. (B, C) Each subject underwent cerebral MRI scanning. T1- and T2-weighted lesion volume and brain parenchymal volume (BPV) were measured using a semi-automated approach [17]. The figures show average T1 and T2 lesion volumes normalized to total BPV. (*p=0.02; non-parametric, one-way ANOVA with Dunn’s multiple comparisons test)